Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANZadapt adaptive versus continuous abiraterone or enzalutamide in metastatic castration-resistant prostate cancer
NL-OMON56330Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abiraterone and enzalutamide in prostate cancer (PCa) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Time to treatment failure while on treatment. Started Dec 2022; status: recruiting.
02
Drugs
abirateroneenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON56330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56330.